%3Aquality(85)%3Aextract_cover()%2F2026%2F06%2F02%2F990%2Fn%2F1922729%2Ftmp_RKTZvr_4a1019e3e51d5d0b_Fabletics_Luxe360.jpg&w=1200&q=75)
New Drug Combination Shows Promise for Cystic Fibrosis Treatment
Drug combo shows potential for treating cystic fibrosis
Stanford Edu
Image: Stanford Edu
Researchers at Stanford Medicine have discovered a synergistic effect between two FDA-approved drugs, formoterol and methacholine, that enhances mucus clearance in cystic fibrosis models. This combination could benefit the 10-20% of patients unresponsive to current treatments, with clinical trials planned for further evaluation.
- 01The combination of formoterol and methacholine significantly improved mucociliary clearance in animal models of cystic fibrosis.
- 02Approximately 10-20% of cystic fibrosis patients do not respond to existing CFTR modulator treatments.
- 03The drug combination was found to be safe and well tolerated in a small group of human subjects, including CF patients.
- 04The findings suggest potential applications for other chronic respiratory diseases, such as chronic obstructive pulmonary disease and bronchiectasis.
- 05The study was funded by several organizations, including the National Institutes of Health and the Cystic Fibrosis Foundation.
Advertisement
In-Article Ad
Researchers from Stanford Medicine have identified a promising drug combination for treating cystic fibrosis (CF) that enhances mucus clearance. The combination of formoterol, a beta adrenergic agonist, and methacholine, a cholinergic agonist, was shown to be safe in a small human trial and significantly improved mucociliary clearance in animal models. This discovery is particularly important for the 10-20% of CF patients who do not respond to existing CFTR (cystic fibrosis transmembrane conductance regulator) modulators. Lead researcher Nam Soo Joo, PhD, expressed hope that this treatment could help CF patients by reducing chronic lung infections. The study also indicated that the drug combination might benefit patients with other respiratory conditions, such as chronic obstructive pulmonary disease and bronchiectasis. Plans for larger clinical trials are underway to evaluate the effectiveness of this treatment in CF patients. The research was supported by multiple institutions, including the National Institutes of Health and the Cystic Fibrosis Foundation.
Advertisement
In-Article Ad
The drug combination may significantly improve the quality of life for cystic fibrosis patients, particularly those who do not respond to current treatments.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of this new drug combination for cystic fibrosis?
Connecting to poll...
More about Stanford Medicine
Read the original article
Visit the source for the complete story.